Table 1 was updated, because Sarilumab, anti-IL-6 receptor mAb has been approved for RA in Japan.
 |
. 2018 Jan 11;94(1):56–57. doi: 10.2183/pjab.94.005
Addendum to “Treatment of rheumatoid arthritis with biological agents — as a typical and common immune-mediated inflammatory disease”
Tsutomu TAKEUCHI
Tsutomu TAKEUCHI
Find articles by Tsutomu TAKEUCHI
© 2018 The Japan Academy
This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
PMCID: PMC6104721 PMID: 29321447
This corrects the article "Treatment of rheumatoid arthritis with biological agents — as a typical and common immune-mediated inflammatory disease" in volume 93 on page 600.